| Year of publication | Reference | Comparative study | Chromatography | Ion source | Specimen | Participants (Case) | Participants (Control) | |||
| Cancer type | Stage | Number | Type | Number | ||||||
Year of publication | Reference | Comparative study | Chromatography | Ion source | Specimen | Participants (Case) | Participants (Control) | |||
Cancer type | Stage | Number | Type | Number | ||||||
| 2011 | Hori et al. 2011 | #1 | GC | – | serum | adenocarcinoma, squamous cell carcinoma, SCLC | I, II, III, IV | 33 | healthy | 29 |
| 2011 | Hori et al. 2011 | #2 | GC | – | serum | adenocarcinoma, squamous cell carcinoma, SCLC | I, II | 11 | healthy | 29 |
| 2011 | Hori et al. 2011 | #3 | GC | – | serum | adenocarcinoma, squamous cell carcinoma, SCLC | III, IV | 22 | healthy | 29 |
| 2011 | Hori et al. 2011 | #4 | GC | – | tissue | adenocarcinoma, squamous cell carcinoma, SCLC | – | 7 | tumor vs. adjacent normal tissue | 7 |
| 2021 | Ahmed et al. 2021 | #1 | LC | ESI | Urine | NSCLC pre-surgery | I, II | 29 | NSCLC post-surgery | 29 |
| 2021 | Ahmed et al. 2021 | #2 | LC | ESI | Serum | NSCLC pre-surgery | I, II | 32 | NSCLC post-surgery | 32 |
| 2013 | Alberg et al. 2013 | #1 | LC | ESI | plasma | lung cancer | – | 100 | healthy | 200 |
| 2010 | An et al. 2010 | #1 | LC | ESI | urine | squamous cell carcinoma, adenocarcinoma, SCLC | – | 19 | healthy | 22 |
| 2010 | An et al. 2010 | #2 | LC | APCI | urine | squamous cell carcinoma, adenocarcinoma, SCLC | – | 19 | healthy | 22 |
| 2010 | An et al. 2010 | #3 | LC | APPI | urine | squamous cell carcinoma, adenocarcinoma, SCLC | – | 19 | healthy | 22 |
| Year of publication | Reference | Comparative study |
| 2011 | Hori et al. 2011 | #1 |
| 2011 | Hori et al. 2011 | #2 |
| 2011 | Hori et al. 2011 | #3 |
| 2011 | Hori et al. 2011 | #4 |
| 2021 | Ahmed et al. 2021 | #1 |
| 2021 | Ahmed et al. 2021 | #2 |
| 2013 | Alberg et al. 2013 | #1 |
| 2010 | An et al. 2010 | #1 |
| 2010 | An et al. 2010 | #2 |
| 2010 | An et al. 2010 | #3 |